Search company, investor...

Axcell Biotechnologies


Acquired | Acquired

About Axcell Biotechnologies

Axcell Biotechnologies is a biopharma company that has developed Spirolept, a vaccine against human leptospirosis marketed in France. In April 2012, Axcell Biotechnologies was acquired by Imaxio. The valuation of Axcell Biotechnologies was undisclosed. Other terms of the deal were not released.

Headquarters Location

Zone Artisanale La Parliere



+33 474 70 09 00

Missing: Axcell Biotechnologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Axcell Biotechnologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Axcell Biotechnologies Frequently Asked Questions (FAQ)

  • What is Axcell Biotechnologies's latest funding round?

    Axcell Biotechnologies's latest funding round is Acquired.

  • Who are the investors of Axcell Biotechnologies?

    Investors of Axcell Biotechnologies include Imaxio.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.